|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Carey LA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492-502. Abstract
Geyer CE et al. A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced metastatic breast cancer (EGF100151). Proc ASCO 2006. No abstract available
Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 46.
Perou CM et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52. Abstract
Slamon D et al, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Sørlie T et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-74. Abstract
 |
 |
